Table 1 Baseline characteristics of US-enrolled participants in the randomized trial of rATG versus basiliximab induction therapy
rATG (n = 91) | Basiliximab (n = 92) | P | |
|---|---|---|---|
Recipient characteristics | |||
Age (years), mean ± standard deviation | 49.6 ± 12.4 | 49.0 ± 13.0 | 0.73 |
Male, % | 58 % | 65 % | 0.36 |
Race, %: | 0.29 | ||
White | 40 % | 53 % | |
Black | 45 % | 40 % | |
Other | 15 % | 8 % | |
Peak panel-reactive antibody level, mean ± standard deviation | 18.7 ± 31.8 | 17.7 ± 30.7 | 0.83 |
Donor characteristics | |||
Age (years), mean ± standard deviation | 42.9 ± 16.3 | 43.4 ± 17.7 | 0.84 |
Donors older than 50 years, % | 44 % | 47 % | 0.77 |
Male, % | 49 % | 58 % | 0.30 |
Race, %: | 0.80 | ||
White | 79 % | 80 % | |
Black | 12 % | 10 % | |
Other | 9 % | 10 % | |
Donation after cardiac death, % | 7 % | 7 % | 0.99 |
Diabetes mellitus, % | 5 % | 3 % | 0.50 |
Hypertension, % | 30 % | 26 % | 0.62 |
Transplant characteristics | |||
Cold ischemia time (hours), mean ± standard deviation | 25.7 ± 9.6 | 26.0 ± 8.4 | 0.82 |
Missing, % | 8.8 % | 7.6 % | 0.77 |
Previous transplantation, % | 5 % | 5 % | 1.00 |